| Gene name: | FGF21 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | Bone marrow |
| Cell name: | MSC |
| Experiment: | SA-β-gal activity assay//Immunostaining//Knockdown |
| Description: | FGF21 siRNA treatment also markedly enhanced SA-β-gal-positivity in P4 BM-MSCs.Ki-67 staining revealed that the number of Ki-67-positive cells was significantly reduced in FGF21 siRNA-treated P4 BM-MSCs compared with control BMMSCs. |
| Target gene: | P53//P21//MFN2//P-DRP1 |
| Official symbol(s): | P53//P21//MFN2//P-DRP1 |
| R-AG-Target gene: | --//--//--//-- |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot |
| Target gene description: | We found that FGF21 siRNA treatment greatly reduced the protein level of FGF21 but upregulated the p53 and p21 protein level in P4 BM-MSCs,Silencing FGF21 with FGF21 siRNA elevated the level of Mfn2 and decreased the level of p-Drp1. |
| Regulatory pathway: | AMPK |
| R-AG-Pathway: | -- |
| Official symbol(s): | PRKAA1 |
| Pathway experiment: | Western blot//Knockdown |
| Pathway description: | Western blotting analysis showed that silencing FGF21 with FGF21 siRNA reduced p-AMPK and p-Drp1 and upregulated the Mfn2 level in P4 BM-MSCs. |
Annotation:
Loading,please wait...